Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...

In its latest update of AXS-05, Axsome reported that the 295-patient phase 3 ACCORD-2 trial met its primary endpoint, with ...

The phase 3 POETYK PsA-1 trial evaluated the drug in patients who were not previously treated with a biologic ...

Kearney Urology Center in the US has reported a 50% reduction in biopsies since adopting a new prostate cancer blood test with “unprecedented accuracy”. The test, EpiSwitch PSE, is the culmination of ...

Austin Lee Resourcing was founded with a clear sense of purpose to provide a high level service that is efficient, genuine and innovative to both our candidates and our clients. Our objective is to ...

UBM Medica UBM Medica is a leading healthcare media company providing bespoke solutions to a global healthcare market. We provide reference data, decision support solutions, news and education to ...

At first glance, translating clinical outcome assessments (COAs) from their original language (most commonly English) to other languages appears to be no more complicated than other trial planning ...

NonStop matches the best people with the right positions. We’re committed to sourcing the top careers, offering you honest advice and sharing practical tips. Our specialist consultants’ in-depth ...

A dynamic medical communications agency helping innovative life sciences companies to Be Heard, Be Understood & Be the Difference.

Gower is recognised as one of the world’s leading publishers of specialist business and management books and resources. Our publishing programme covers many of the main business processes and ...

BeiGene’s PD-1 inhibitor Tevimbra (tislelizumab-jsgr) has been granted approval by the US Food and Drug Administration (FDA) as part of a first-line combination treatment for advanced gastric cancer.

Novo Nordisk has announced an investment of 8.5bn Danish kroner, or approximately $1.2bn, to establish a new rare disease production facility in Odense, Denmark. Construction on the new site, which ...